Related Experiment Video
Updated: Sep 27, 2025
06:08
A Novel Method: Super-selective Adrenal Venous Sampling
Published on: September 15, 2017
23.6K
Aldosterone breakthrough from a pharmacological perspective
1Department of Pharmacology, Ehime University, Graduate School of Medicine, Shitsukawa, Tohon, Ehime, 791-0295, Japan. mmogi@m.ehime-u.ac.jp.
Summary
Aldosterone breakthrough, a complication of long-term RAAS blockade, increases cardiovascular risk in hypertensive patients. Understanding its mechanisms is crucial for managing resistant hypertension and improving patient outcomes.
Area of Science:
- Endocrinology
- Cardiovascular Medicine
- Pharmacology
Background:
- Aldosterone breakthrough is a known complication in patients on long-term renin-angiotensin-aldosterone system (RAAS) blockade.
- Mineralocorticoid receptor (MR) blockade effectively manages resistant hypertension but isn't a first-line treatment.
- Aldosterone breakthrough elevates cardiovascular disease risk and worsens patient prognosis.
Purpose of the Study:
- To review aldosterone secretion and the mechanisms underlying aldosterone breakthrough.
- To explore the pharmacological aspects of aldosterone breakthrough, both RAAS-dependent and independent.
- To discuss hypothetical views on aldosterone breakthrough.
Main Methods:
- Literature review of aldosterone secretion and breakthrough mechanisms.
- Analysis of pharmacological data related to RAAS inhibitors and MR blockers.
- Synthesis of current understanding and hypothetical perspectives.
Main Results:
- Aldosterone breakthrough is a complex phenomenon with multifactorial causes.
- RAAS-dependent and independent pathways contribute to aldosterone breakthrough.
- Pharmacological interventions targeting the RAAS and MR are key considerations.
Conclusions:
- Aldosterone breakthrough poses significant risks for hypertensive patients, particularly those with resistant hypertension.
- Further research into the mechanisms and management of aldosterone breakthrough is warranted.
- Understanding aldosterone's role is vital for optimizing antihypertensive therapies.
Keywords:
Aldosterone breakthroughAngiotensin II type 1 receptorMineralocorticoid receptorReceptor functionβ-arrestinMore Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
539
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
539
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
825
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
825
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
1.1K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.1K
01:33Hormonal Regulation
33.7K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
33.7K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
862
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
862
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
981
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
981